The cerebrospinal fluid soluble TREM‐1 concentration in Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI)

Abstract

AbstractBackgroundThe most prevalent form of dementia in the world is Alzheimer Disease (AD), a common neurodegenerative condition. Amyloid peptides, phosphorylated tau proteins, and neuroinflammation are the disease’s hallmarks. Finding new biomarkers that can assist in early AD detection is crucial due to the late appearance of the disease symptoms. Triggering receptor expressed on myeloid cell 1 (TREM‐1) is hypothesized that may contribute to the development of AD by causing neuroinflammation. Due of its significance in inflammatory responses, it has been regarded as a promising biomarker. Literature data indicate that TREM‐1 could be potential biomarker of AD severity. Therefore the purpose of our research was to measure the concentration of soluble TREM‐1 in cerebrospinal fluid of AD and MCI patients and non‐demented controls and compare it with classical AD biomarkers.MethodThe concentrations of TREM‐1 were measured in cerebrospinal fluid (CSF) of 20 AD patients and 15 MCI patients as well as 11 non‐demented controls using multiplexing method. Classical biomarkers, such as Aβ‐42, Aβ‐42/Aβ‐40, tau and pTau181 were assessed by immunoenzyme assays.ResultTREM‐1 concentrations were significantly higher in AD and MCI patients in comparison to non‐demented controls. Moreover, in MCI patients, the levels of this protein were significantly higher than in AD patients. Additionally, increased CSF levels of TREM‐1 correlated positively with Tau, pTau181 in the whole study group.ConclusionFindings of our research suggest that TREM‐1 could be early indicator of AD pathology. However, follow‐up studies on larger study group are needed.